Compare Supplements

Prescription dosing is 75 mg or 150 mg subcutaneously every 2 weeks (a 300 mg every-4-weeks option exists), titrated by a clinician to the LDL-C target. A prescription drug; not a self-administered supplement regimen.

Any time

Subcutaneous prefilled pen/syringe (alirocumab)

Standard approved dosing is 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly, under a clinician. A prescription drug; this is informational, not a recommendation.

Any time

Subcutaneous prefilled autoinjector (evolocumab)

• Known serious hypersensitivity to alirocumab or excipients
• Pregnancy (limited data; lipid lowering generally deferred in pregnancy)

• Statins
• Other lipid-lowering agents (ezetimibe)

• Prior serious hypersensitivity reaction to evolocumab
• Use only under clinician direction as part of a lipid-management plan

• Statins
• Ezetimibe